| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 1,122.39 | 951.89 | 17.91 | ||
| Gross Profit (Loss) | 416.02 | 364.05 | 14.28 | ||
| Operational Profit (Loss) | 291.78 | 131.23 | 122.34 | ||
| Net Profit (Loss) after Zakat and Tax | 257.34 | 90.09 | 185.65 | ||
| Total Comprehensive Income | 251.27 | 92.63 | 171.26 | ||
| Total Share Holders Equity (after Deducting Minority Equity) | 1,710.56 | 1,659.29 | 3.09 | ||
| Profit (Loss) per Share | 1.61 | 0.56 | |||
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is | The company net profit for the year ended 31 December 2022 increased by 185.65% to record SAR 257.34 million compared to SAR 90.09 million in FY 2021. Net profit growth was mainly driven by the following: |
• Revenue growth of 17.91% in FY 2022 versus the previous year supported by solid year-on-year expansions of 18.00% and 17.60% at the medical services and pharmaceuticals segments, respectively. Growth at the medical services segment resulted from rising inpatient and outpatient volumes during FY 2022 compared to FY 2021.
• A decreased in expected credit loss provision of 64.82% versus the previous year. The notable decreased to SAR 54.34 million in FY 2022 from SAR 154.47 million in FY 2021 reflects the update to data related to the amounts expected to be recovered and used in the model for calculating expected credit losses in accordance with the requirements of IFRS No. (9).
• The loss from discontinued operations at Al Hammadi Olaya Hospital during the previous year (FY 2021) which amounted to SAR 8.78 million. The facility has been temporarily shut down to to build a new hospital to replace it.
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.